Biomerica Reports 59.4% Pain Relief, 68.1% Bloating Reduction; Medicare Reimburses $300
In a real-world analysis of 69 IBS patients, Biomerica’s inFoods® therapy achieved a ≥30% reduction in abdominal pain in 59.4% and bloating in 68.1% of participants over 8 weeks. CMS established a $300 national Medicare payment rate for the inFoods® IBS test starting January 1, 2026, bolstering its commercial potential.
1. Real-World Responder Analysis
Biomerica evaluated 69 IBS patients over an 8-week study and found 59.4% achieved at least 30% reduction in abdominal pain and 68.1% saw similar bloating relief, using the FDA-recognized responder endpoint consistent with its peer-reviewed randomized trial.
2. Medicare Reimbursement and Coding
CMS established a $300 national Medicare payment rate for the inFoods® IBS test effective January 1, 2026, and a unique AMA-approved CPT® PLA code simplifies billing for physicians and laboratories.
3. Strategic Partnerships
In late 2025, Biomerica entered a marketing services agreement with Henry Schein, granting access to over 400 field sales representatives targeting gastroenterology and primary care practices, while using CMS pricing as a benchmark in private insurer negotiations.